Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Matthew Zamora

Internal Medicine Bay City, MI Physician Assistant

NPI 1659883676 CMS profile 4210126

4818 S Professional Dr, Bay City, MI 48706

Open in the dashboard

General payments

$5,425

306 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Matthew Zamora of Bay City, MI is reported in the CMS Open Payments database as having received $5,425 across 306 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $180 7
2024 General $1,466 73
2023 General $1,852 103
2022 General $1,320 82
2021 General $608 41

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Matthew Zamora
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Matthew Zamora were reported at $180. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Matthew Zamora Internal Medicine median Middle half National median
2019 $0 $159 $48–$570 $163
2020 $0 $119 $33–$402 $114
2021 $608 $135 $37–$521 $132
2022 $1,320 $141 $42–$496 $149
2023 $1,852 $149 $45–$519 $160
2024 $1,466 $154 $47–$537 $164
2025 $180 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Lilly USA, LLC $755 55 payments
  2. AbbVie, Inc. $634 22 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $593 36 payments
  4. Novo Nordisk Inc $570 32 payments
  5. GlaxoSmithKline, LLC. $402 36 payments
  6. Amgen Inc. $366 17 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $331 19 payments
  8. Astellas Pharma US Inc $313 7 payments
  9. Bayer HealthCare Pharmaceuticals Inc. $258 16 payments
  10. Novartis Pharmaceuticals Corporation $237 12 payments
  11. Other $969 54 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $5,221 301 payments
  2. Education $205 5 payments
Products named General payments · program years 2021–2025
  1. TRINTELLIX $545 33 payments
  2. MOUNJARO $442 30 payments
  3. Wegovy $369 19 payments
  4. QULIPTA $322 8 payments
  5. TRELEGY ELLIPTA $278 30 payments
  6. Kerendia $258 16 payments
  7. JARDIANCE Diabetes $215 17 payments
  8. JARDIANCE Diabetes $206 13 payments
  9. VRAYLAR $176 12 payments
  10. Repatha $175 10 payments
  11. Other $3,246 184 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 120 drugs

Part D claims

5,198

Median for Physician Assistant: 241

Drug cost

$585,500

Median for Physician Assistant: $4,110

Branded share of claims

22.7%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 107 $89,416
Enbrel Sureclick Etanercept Brand 11 $78,957
Jardiance Empagliflozin Brand 65 $76,372
Ozempic Semaglutide Brand 56 $55,493
Mounjaro Tirzepatide Brand 45 $45,710
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 49 $40,654
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 39 $27,525
Trulicity Dulaglutide Brand 21 $21,925
Farxiga Dapagliflozin Propanediol Brand 19 $21,814
Januvia Sitagliptin Phosphate Brand 22 $16,543

The 10 drugs with the highest cost, of 120 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 26 billing codes

Paid by Medicare

$30,537

Medicare's payments for the services billed

Medicare patients

202

Average age 72

Services billed

539

112 women, 90 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 55%
Ischemic heart disease 39%
Depression 34%
Diabetes 30%
COPD 28%
Atrial fibrillation 27%
Chronic kidney disease 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 27 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
QULIPTA
  • AbbVie, Inc. $204
$204 11 —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $161
$161 — —
Wegovy
  • Novo Nordisk Inc $154
$154 — —
VRAYLAR
  • AbbVie, Inc. $117
$117 — —
ENTRESTO
  • Novartis Pharmaceuticals Corporation $89
$89 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 27 with Patron

Records

306 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record